Tolerability and Safety of 40 mg and 100 mg Duloxetine BID Given Over 7 Days in Healthy Female Subjects. A Randomised, Placebo-controlled Double-blind Trial.

Boehringer Ingelheim0 个研究点目标入组 32 人开始时间: 2003年6月最近更新: 2014年9月5日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Boehringer Ingelheim
入组人数: 32
主要终点: Number of subjects with clinically relevant findings in electrocardiogram (ECG)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

Study to assess the safety and tolerability of 100 mg of duloxetine BID compared to 40 mg of duloxetine BID or placebo for 7 days

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double

入排标准

年龄范围: 40 Years 至 —（Adult, Older Adult）
性别: Female
接受健康志愿者: 是

入选标准

•Healthy female subjects as determined by results of screening
•Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
•Age ≥ 40 years
•BMI ≥ 18.5 and ≤ 29.9 kg/m2

排除标准

•Any finding at any of the medical examinations (including blood pressure, pulse rate and ECG (electrocardiogram)) deviating from normal and of clinical relevance (resting heart rate greater than 100 bpm or tachyarrhythmia)
•History of or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders (except thyroid hormones and hormonal replacement therapy)
•History of relevant orthostatic hypotension, fainting spells and blackouts
•Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
•Chronic or relevant acute infections
•History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator, any bleeding disorder including prolonged or habitual bleeding, other hematologic disease, cerebral bleeding (e.g. after a car accident), commotio cerebri
•Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration
•Use of any drugs that might influence the results of the trial (especially CYP2D6 or CYP1A2 modulating substances) within 2 weeks prior to administration or during the trial
•Participation in another trial with an investigational drug within 2 months prior to administration or during trial
•Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
•Alcohol abuse (> 60 g/day)
•Caffeine abuse (> 4 cups/day)
•Drug abuse
•Blood donation within 1 month prior to administration or during the trial
•Excessive physical activities within 10 days prior to administration or during the trial
•Any laboratory value outside the clinically accepted reference range
•Ineffective contraception

研究组 & 干预措施

Duloxetine - low dose

Experimental

干预措施: Duloxetine - low dose (Drug)

Duloxetine - high dose

Experimental

干预措施: Duloxetine - high dose (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)